Gilead terminates adefovir program
Development of anti-HIV agent adefovir dipivoxil has been halted after FDA indicates to the company that it intends to issue a "not approvable" letter by the Dec. 29 user fee deadline. An FDA advisory committee recommended Nov. 1 that Gilead gather additional efficacy data to support the proposed 60 mg dose of adefovir. However, "Gilead has determined that an additional investment of time and resources in this products is not appropriate given the other opportunities in Gilead's clinical pipeline," including the related compound tenofovir, which has moved into Phase III. Adefovir will continue to be developed at lower doses for hepatitis B. Patients in HIV trials will be able to join the adefovir expanded access program, Gilead said. Gilead expects only "minimal" obligations by the end of 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth